{"filing":{"accession_number":"0001213900-26-087221","cik":"0001840877","ticker":"COCHW","company_name":"Envoy Medical, Inc.","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"ea0301372-8k_envoy.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1840877/000121390026087221/ea0301372-8k_envoy.htm"},"events":[{"id":26500,"run_id":24087,"accession_number":"0001213900-26-087221","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses financial results including net revenue of $51 thousand, operating expenses, and net loss of $7.3 million, along with key operational milestones (FDA PMA submission, clinical trial data). The filing includes condensed consolidated balance sheets and is material to investors assessing the company's financial position and progress toward commercialization of its Acclaim cochlear implant.","company_name":"Envoy Medical, Inc.","ticker":"COCHW","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27642,"accession_number":"0001213900-26-087221","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses financial results including net revenue of $51 thousand, operating expenses, and net loss of $7.3 million, along with key operational milestones (FDA PMA submission, clinical trial data). The filing includes condensed consolidated balance sheets and is material to investors assessing the company's financial position and progress toward commercialization of its Acclaim cochlear implant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:02:52.811198+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27642,"accession_number":"0001213900-26-087221","item_number":"2.02","item_title":"Results of Operations and Financial","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This is a standard quarterly earnings release for Q2 2026 ended June 30, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses financial results including net revenue of $51 thousand, operating expenses, and net loss of $7.3 million, along with key operational milestones (FDA PMA submission, clinical trial data). The filing includes condensed consolidated balance sheets and is material to investors assessing the company's financial position and progress toward commercialization of its Acclaim cochlear implant.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T20:02:52.811198+00:00","company_name":"Envoy Medical, Inc.","ticker":"COCHW","filing_date":"2026-08-10"}]}